Novo Nordisk CEO Mike Doustdar told the Financial Times the company is open to a direct listing on the New York Stock Exchange. This potential move would replace the Danish pharmaceutical giant's current American depositary receipts.
Doustdar cited the growing importance of the U.S. market, which generates over 50% of the company's revenue. American investors also comprise a significant portion of the firm's investor base.
Internal teams discussed the listing transition periodically over the last decade. Doustdar clarified that the company is not currently exploring the option or holding active dialogues. These comments signal a potential long-term strategy to enhance the company's profile and accessibility for U.S. investors.